AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2003 APR 10 - (NewsRx.com & NewsRx.net) -- Cerivastatin quells molecular mechanisms that cause breast cancer aggression.
"Statins are currently used for the treatment of hypercholesterolemia. Recently, we demonstrated that cerivastatin also reduces the proliferation and invasion of aggressive breast cancer cells, MDA-MB-231. In this report, a molecular mechanism to explain its anti-cancer action is proposed by combining the study of cerivastatin effect on both gene expression (microarray) and signal transduction pathways," researchers in France report.
"Firstly, the expression of 13 genes was modified by cerivastatin and confirmed at protein level. They could contribute to the inhibition of both cell proliferation (down-regulation of cyclin D1, PCNA, c-myc and up-regulation p21(wafl), p19(INK4d) integrin beta8) and cell invasion, either directly (decrease in u-PA, MMP-9, u-PAR, PAI-1 and increase in anti-oncogenes Wnt-5a and H-cadherin) or indirectly by stimulating an antiangiogenic gene (thrombospondin-2). The antiangiogenic activity was confirmed by in vivo experiments," wrote C. Denoyelle and colleagues, UFR Medicine and Pharmacy.
"Secondly, we demonstrated that the biochemical mechanism of its anti-cancer action could be mainly explained by the inhibition of RhoA-dependent cell signaling. This hypothesis was supported by the fact that a RhoA inhibitor (C3 exoenzyme) or a ...